Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Manabu, Masuzawa"'
Publikováno v:
Hepatology Research. 28:73-78
Interferon (IFN) alfa-2a was administered to 23 patients with chronic hepatitis B daily for 4 weeks and the relation between the efficacy of the treatment and changes in total hepatitis B virus (HBV) DNA and precore mutant levels was investigated. At
Autor:
Norio Hayashi, Kazuhiro Katayama, Tsutomu Kanda, Michio Kato, Akinori Kasahara, Shinji Kubota, Taizo Hijioka, Manabu Masuzawa, Harumasa Yoshihara
Publikováno v:
Kanzo. 44:222-229
Autor:
Noriko Okada, Hirohisa Tanimura, Keisuke Hashimoto, Haruya Meren, Hiroaki Murata, Manabu Masuzawa, Hiroki Akamatsu, Mitsuhiko Kubo, Sunao Kawano, Takashi Abe, Jun Tanabe, Tamotsu Hayashi
Publikováno v:
Digestive Endoscopy. 15:64-68
Dieulafoy's ulcer is a rare form of gastrointestinal bleeding. Although the original descriptions and early reports were of lesions in the proximal stomach, similar lesions have subsequently been reported in the esophagus, duodenum, jejunum, colon an
Autor:
Masahiro Kimura, Masaki Ikemoto, Manabu Masuzawa, Akira Kaneko, Michio Kato, Yoshiyasu Yabusaki, Yukiko Izumi, Nobuyuki Amino, Yoh Hidaka, Ke-ita Tatsumi, Hisato Tada
Publikováno v:
Clinica Chimica Acta. 316:155-164
Background : Antibodies to cytochrome P4502D6 (CYP2D6) were measured and their prevalence compared with that of antibodies to liver-specific arginase in patients with autoimmune hepatitis (AIH). Methods : Anti-CYP2D6 antibodies were measured by sensi
Autor:
Keiji Yamamoto, Kenya Iyoda, Masahiro Ikeda, Masato Komori, Yoshimi Kakiuchi, Manabu Masuzawa, Michio Kato, Nobukazu Yuki, Yasunori Sugiyasu, Eriko Fujii, Akira Kaneko, Kazuhei Kurosawa
Publikováno v:
Journal of Clinical Gastroenterology. 31:297-301
Approximately half of all patients with chronic hepatitis C show an initial biochemical response to interferon, but only 15% to 20% of patients achieve a sustained response. We studied the efficacy of retreatment with interferon for patients with chr
Autor:
Manabu Masuzawa, Norio Hayashi, Masahide Oshita, Naoki Hiramatsu, Akinori Kasahara, Masafumi Naito, Kiyoshi Mochizuki, Masatsugu Hori, Michio Kato, Tooru Kashiwagi, Takenobu Kamada, Harumasa Yoshihara
Publikováno v:
Hepatology Research. 16:124-138
Background: The selection of hepatitis C virus (HCV)-related cirrhotic patients for interferon treatment is necessary to improve the efficacy of this treatment. Currently, it is impossible to predict which cirrhotic patients will ultimately respond t
Autor:
Manabu Masuzawa, Nobukazu Yuki, Michio Kato, Michikazu Kono, Akinori Kasahara, Kenya Iyoda, Norio Hayashi, Teruhisa Akeyama
Publikováno v:
Kanzo. 41:323-327
C型慢性肝炎に対する初回インターフェロン治療で再燃を示した42例を対象に10カ月間のIFN再投与を施行し, その有効性と治療効果に影響する因子を検討した. 投与法はrIFNα2a9MUを2週間連日
Autor:
Hisashi Ishida, Masatsugu Hori, Yoshiki Matsushita, Norio Hayashi, Yutaka Sasaki, Manabu Masuzawa, Hiroshi Kishimoto, Michio Kato, Tsutomu Tabata, Nobukazu Yuki, Takashi Inoue
Publikováno v:
Journal of Medical Virology. 59:431-436
A novel hepatitis-associated DNA virus, designated as transfusion-transmitted virus (TTV), was identified recently. We investigated the frequency of TTV viremia in hepatitis C virus (HCV) carriers on maintenance hemodialysis to determine whether TTV
Autor:
Akinori Kasahara, Terukazu Ito, Teruhisa Akeyama, Kazuhiro Katayama, Hideyuki Fusamoto, Takenobu Kamada, Norio Hayashi, Harumasa Yoshihara, Masami Moriyama, Manabu Masuzawa, Youji Shimizu, Yutaka Kishida
Publikováno v:
Hepatology Research. 14:212-222
The efficacy of weekly administration of interferon (IFN)-β in patients with type B chronic active hepatitis positive for e antigen was investigated. Subjects were 27 patients. Thirteen (Group A) were assigned to a treatment group given three millio
Autor:
Michikazu Kouno, Yutaka Sasaki, Takenobu Kamada, Akinori Kasahara, Taizo Hijioka, Tomoyuki Mukuda, Atsuo Inoue, Junnosuke Kojima, Harumasa Yoshihara, Teruhisa Akeyama, Norio Hayashi, Michio Kato, Manabu Masuzawa
Publikováno v:
Kanzo. 40:445-453
IFN治療難治例と考えられる1b型高ウィルスC型慢性活動性肝炎に対するIFN-β3MU1日2回4週間連日投与後rIFN-α2b10MU週3回12週間投与の有用性をIFN-β6MU1日1回4週間連日投与後rIFN-α2b10MU週3回12週間